PREVENT Cancer Preclinical Drug Development Program (PREVENT) 2015
IDIQ
Overview
Ceiling
$29,800,000
Primary Sponsoring Agency
Who Can Use
One Agency
Primary NAICS
Primary Set Aside
None
Extent Competed
Full And Open Competition
Related Opportunity
PREVENT Cancer Preclinical Drug Development Program (PREVENT) 2015 awarded by National Cancer Institute (NCI) in September 2015 accepts orders through September 2018.
The IDIQ has a reported ceiling of $29,800,000, and as of today, $29,343,318 has been obligated through the vehicle.
The IDIQ was awarded
full & open and has a primary NAICS code of 541711.
Status
Period of Performance
9/22/15
Start Date
9/21/18
Ordering Period End Date
Task Order Obligations
$29.3M
Total Obligated
$29.3M
Current Award
$29.3M
Potential Award
Vehicle Award Share
Contractors with greatest percentage of obligations for PREVENT Cancer Preclinical Drug Development Program (PREVENT) 2015
Vehicle Award Share
Federal Award Analysis
PREVENT Cancer Preclinical Drug Development Program (PREVENT) 2015 contract spending
$-
Contracts
$-
Subcontracts
$-
Grants
$-
Subgrants
$-
Total
No Results
Calculating
Calculating
No Results
Calculating
Calculating
No Results
Calculating
Calculating
| Year | Contracts | Subcontracts | Grants | Subgrants |
|---|
No Results
Calculating
Calculating
No Results
Calculating
Calculating
Awardees
PREVENT Cancer Preclinical Drug Development Program (PREVENT) 2015 awardees
Contract Awards
PREVENT Cancer Preclinical Drug Development Program (PREVENT) 2015 task orders
Subcontract Awards